Fair Value Measurement

6 Months Ended

Jun. 26, 2011

Fair Value Measurement

Fair Value Measurement

Note 9 — Fair value measurement

For a description of the fair value hierarchy, see Note 10 to the Company's 2010 consolidated financial statements included in its current report on Form 8-K for the year ended December 31, 2010.

The following tables provide information regarding the financial assets and liabilities carried at fair value measured on a recurring basis as of June 26, 2011 and December 31, 2010:

	Total carrying value at June 26, 2011		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
	(Dollars in thousands)
Cash and cash equivalents	$	65,000	$	65,000	$	—	$	—
Bonds - foreign government		6,915		6,915		—		—
Investments in marketable securities		4,209		4,209		—		—
Derivative assets		419		—		419		—
Derivative liabilities		19,128		—		19,128		—
Contingent consideration liabilities		9,530		—		—		9,530
	Total carrying value at December 31, 2010		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
	(Dollars in thousands)
Investments in marketable securities	$	4,108	$	4,108	$	—	$	—
Derivative assets		880		—		880		—
Derivative liabilities		25,200		—		25,200		—

The following table provides a reconciliation of changes in Level 3 financial liabilities measured at fair value on a recurring basis for the six month period ending June 26, 2011:

	Contingent consideration
	(Dollars in thousands)
Balance at beginning of year	$	—
Initial estimate of contingent consideration		15,400
Payment		(6,000	)
Revaluations		130
Balance at end of period	$	9,530

See Note 7, "Borrowings," for a discussion of the fair value of the Company's long-term debt.

Valuation Techniques Used to Determine Fair Value

The Company's cash and cash equivalents valued based upon Level 1 inputs are comprised of overnight investments in money market funds. The funds invest in obligations of the U.S. Treasury, including Treasury bills, bonds and notes. The funds seek to maintain a net asset value of $1.00 per share.

The Company's financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to pay benefits under certain deferred compensation plans and other compensatory arrangements and zero coupon Greece government bonds. The investment assets of the trust are valued using quoted market prices multiplied by the number of securities held in the trust. The Greece government bonds were received in settlement of amounts due to the Company from sales to the public hospital system in Greece for 2007, 2008 and 2009. The bonds mature over three years. The fair value of the bonds is determined based on quoted prices in active markets for identical assets.

The Company's financial assets valued based upon Level 2 inputs are comprised of foreign exchange contracts. The Company's financial liabilities valued based upon Level 2 inputs are comprised of an interest rate swap contract and foreign exchange contracts. The Company uses foreign exchange contracts to manage foreign currency transaction exposure and the interest rate swap is used to reduce exposure to interest rate changes. The fair value of the foreign exchange contracts represents the amount required to enter into offsetting contracts with similar remaining maturities based on quoted market prices. The fair value of the interest rate swap contract is developed from market-based inputs under the income approach using cash flows discounted at relevant market interest rates. The Company has taken into account the creditworthiness of the counterparties in measuring fair value. See Note 8, "Financial instruments" for additional information.

The Company's financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration pertaining to the VasoNova acquisition. The fair value of the contingent consideration is determined using a weighted probability of potential payment scenarios discounted at rates reflective of the Company's credit rating and expected return on the VasoNova business. The assumptions used to develop the estimated amount recognized for the contingent consideration arrangement are updated each reporting period. The second quarter changes in the discount rates and the timing of expected pay-outs resulted in an additional accrual of approximately $0.1 million. As of June 26, 2011, the Company has recorded approximately $3.9 million of contingent consideration in other current liabilities and the remaining $5.6 million in other liabilities.